Hey Google, does this patient have sacroilitis? Artificial intelligence model validated for detection of radiographic sacroilitis. @RheumNow #ACR20 Abs#2018 https://t.co/TDhGKC8ss4

What was the effect of COVID-19 in axSpA patients? From @rheum_cat In the early phase of COVID-19 there was a higher levels of stress and anxiety leading to higher BASDAI scores @RheumNow #ACR20 Abstr#1884

Abst#2001: Heme changes on MTX? CIRT trial (non-rheumatic pts): Low-dose MTX (15-20mg/w): 2 line cytopenia uncommon (4%), pancytopenia rare (0.5%), Hb decrease 0.4 g/dL but WBC, plt unchanged. Reassuring large pop study shows tolerance of MTX #ACR20 @Rheumnow

Abst#2000. PRIME team Medicare database study pts with new RA started on MTX higher VTE risk than HCQ (HR 2.3). Unable to assess disease activity because claims database, but would imagine MTX grp more severe, driving increased VTE risk @RheumNow #ACR20 https://t.co/Z14xFTVXTp

The majority of patients with axSpA were able to use an axSpA smartphone app. recording BASDAI, BASFI 2 weekly. Current disease activity influence adherence to reporting @RheumNow #ACR20 Abstr#1890

Test your ACR IQ and see where you place on our leaderboard. #ACR20 https://t.co/DKSq8gKTDb https://t.co/lGUEbVbg1g

• https://bit.ly/36hztGB

2020 #ACR20 RA guidelines were against steroid usage in RA. ESPOIR French cohort: 10 years of very low dose GC show increase events (death/CVD/fracture/severe ifn) even on low doses. HR increases every year. Cum GC dose-effect esp ifn, CVD. @RheumNow #ACRBest https://t.co/7b7chCPRxm

COX2 inhibitors associated with inhibition of radiographic spinal progression in AxSpA pts compared to non-selective NSAIDs. ⬇️radiographic spinal progression over 2 yrs ⬇️mSASSS progression @RheumNow #ACR20 Abs#2030 https://t.co/p1CeNBm3ma

Another great late-breaking asbtract: #HerpesZoster in patients w/ #rheumatoidarthritis taking #upadacitinib #JAKinhibitor -HZ events more common in patients taking 30mg vs 15mg -HZ more common in UPA vs those taking ADA+MTX & MTX Abs#2002 #ACR20 @RheumNow https://t.co/tQ03wBueW5

• Incidence and Risk Factors for Herpes Zoster in Rheumatoid Arthritis Patients R…

We as young physicians should start paying attention to our contracts-🤦‍♀️ 1-know your worth (see MGMA compensation yearly) 2-malpractive/ tail coverage 3-non-compete 4-termination clause 5-guarantee/ RVU @RheumNow #ACR20 #5M036

Mavrilimumab (anti-GM-CSF) in GCA, phase 2 GM-CSF upstream to both Th1 & Th17 pathways; potential for dx-modifying?? PNL induction then enrol+PNL taper GCA flare (ESR/CRP+Sx/imaging): mavrilimumab RRR 62% Enormous potential, worth exploring! Cid et al #ACR20 ABSTL06 @RheumNow https://t.co/mq5sTVGbPs

RheumNow’s expanded coverage of the #ACR20 Annual meeting is sponsored in part by @Novartis. All content chosen by RheumNow and its Faculty.